| Title |
Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
|
|---|---|
| Published in |
PLOS ONE, March 2013
|
| DOI | 10.1371/journal.pone.0059314 |
| Pubmed ID | |
| Authors |
Xiaofeng Chen, Yiqian Liu, Oluf Dimitri Røe, Yingying Qian, Renhua Guo, Lingjun Zhu, Yongmei Yin, Yongqian Shu |
| Abstract |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). The studies are quite heterogenous regarding study size and populations, and a synopsis of these data could give some more insight in the role of maintenance therapy with TKI. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 1% |
| France | 1 | 1% |
| Slovenia | 1 | 1% |
| Unknown | 67 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 19% |
| Other | 10 | 14% |
| Student > Bachelor | 9 | 13% |
| Student > Master | 8 | 11% |
| Student > Ph. D. Student | 8 | 11% |
| Other | 13 | 19% |
| Unknown | 9 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 37% |
| Agricultural and Biological Sciences | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Nursing and Health Professions | 4 | 6% |
| Other | 11 | 16% |
| Unknown | 13 | 19% |